Business
From LinkedIn regarding Techcyte and Biobase partnership Sam Seymour, CPO and Co-Founder at Biobase: I started in digital pathology over 6 years ago at Paige (now Tempus AI). Not a lot has changed since then; digital pathology's adoption...
Agreement includes a license for Owkin AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly...
Regarding the Roche acquisition of PathAI, from Elizabeth Bourn on LinkedIn: This morning, Roche announced that it had entered into a definitive merger agreement to acquire PathAI for $750M upfront, with up to $300M in additional milestone...
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong position in...
Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced the completion of a $15 million capital raise led by Van Tuyl Companies, with participation from existing investors Zoetis Inc....
The latest from the Proscia blog: By Ritida Nanda | March 12, 2026 Proscia has been named Global 2026 Best in KLAS for Digital Pathology in Europe and earned the top performance score in the U.S. in the 2026 KLAS Digital...
